Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2017
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Enanta Pharmaceuticals (ENTA) PT Raised to $38 at JPMorgan
August 8, 2017 8:45 AM EDTJPMorgan raised its price target on Enanta Pharmaceuticals (NASDAQ: ENTA) to $38.00 (from $32.00) while maintaining a Overweight rating.
... MoreEnanta Pharmaceuticals (ENTA) PT Raised to $36 at Baird; Remains Sidelined
August 8, 2017 7:19 AM EDTBaird raised its price target on Enanta Pharmaceuticals (NASDAQ: ENTA) to $36.00 (from $27.00) while maintaining a Neutral rating following the company's 3Q. AbbVie's reported sales of $225M for Viekira were largely in line with estimates. Enanta earned $7.5M in royalty revenue on these sales, versus... More
Enanta Pharma (ENTA) Tops Q3 EPS by 4c. Revs Miss
August 7, 2017 4:01 PM EDTEnanta Pharma (NASDAQ: ENTA) reported Q3 EPS of ($0.44), $0.04 better than the analyst estimate of ($0.48). Revenue for the quarter came in at $7.5 million versus the consensus estimate of $8.14 million.
For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.
... More